Clinical trials of Ketas Ibudalist for asthma and ALS.
Clinical trials of Ketas: tested medicine for ALS and respiratory diseases.
Ketas tablets, also known under the trademark of Ibudalist, is one of the few medicines used to treat several diseases at once, including asthma, fibromyalgia and ALS. Medicine has three proven therapeutic effects:
- Neuroprotective effect. Protection of neural tissue and connections.
- The effect of vasodilation, relaxation of vascular smooth muscle.
- Bronchodilatory effect, removing bronchospasm.
These three effects combined together make Ketas Ibudalist popular and, most importantly, rather effective medicine for treatment of ALS disease (approved by the US FDA and the European EMA as orphan drug for the treatment of ALS), as well as for the treatment of all types of bronchial asthma. Ketas is one of the few medicines that is able to overcome the hematoencephalic barrier (blood-brain barrier), the physiological barrier between the circulatory system and the central nervous system, including the human brain. Due to this ability, it exerts on neural cells and activates neural connections. Thanks to these features, Kteas Ibudalist from Japan effectively deals with neuropathic pains, including fibromyalgia, while not causing addiction and not weakening its effect with time, unlike other standard painkillers.
Ketas Ibudalist medicine for asthma and ALS, as was mentioned before, has two main directions of application in medicine: treatment of bronchial asthma, and treatment of pathological conditions of brain vessels (including the effects of strokes and ALS). In this case, the drug does not show serious side effects. Side effects include loss of appetite in 0.58% of cases, as well as mild nausea in 0.56% of clinical trials.
Clinical trials of Ketas Ibudalist: general overview.
Clinical trials of the drug Ketas Ibudalist were conducted in 2002 by Dr. Sinohara Yukito - this medicine showed a significant improvement of patients with bronchial asthma on average in 75% of cases. Separately, studies have been conducted on the effect of Ketas Ibudalist on the brain of people who have had a stroke. Due to the complexity of such studies, placebo-controlled studies were carried out, and the results exceeded all expectations - the effectiveness of Keta Ibulalist tablets from Japan exceeded placebo test effects by more than 300%, giving tangible improvements in the majority of cases observed. (official information on certification and clinical trials are available here).
In Japan, targeted studies on the effects of Ketas Ibudalist on the symptoms and conditions of ALS were not completed when this article was published, but in 2016 the drug was approved by the US Supervisory Authority for Medicines (FDA), and in 2017 the European Medical Organization (EMA) recognized the effectiveness of the drug for the treatment of ALS disease as medicine for the treatment of diseases of particular complexity in the absence of 100% effective alternative methods.
You can also check the following related articles in our blog about ALS and neuropatic pain treatment: